Reneo Pharmaceuticals (RPHM) said late Wednesday that its shareholders voted in favor of a proposed merger of the company with OnKure.
Following the anticipated Friday closing of the deal, the combined company will change its name to OnKure Therapeutics and trade on Nasdaq under the ticker symbol "OKUR."
The new company will be led by OnKure's management team and focus on advancing drug candidates targeting oncogenic mutations for the treatment of solid tumors.
The company said it will also implement a 1-for-10 reverse stock split effective immediately before the closing of the merger and begin trading Monday on a split-adjusted basis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.